NexCAR19 CAR-T Trial for B-Cell Malignancies in Turkey
Summary
ClinicalTrials.gov registered a new CAR-T cell therapy trial (NCT07502118) evaluating NexCAR19 for treatment of B-cell malignancies in Turkey. The study is listed as a single-arm trial investigating a locally manufactured CAR-T product in patients with relapsed or refractory B-cell cancers.
What changed
ClinicalTrials.gov has registered a new clinical trial (NCT07502118) for NexCAR19, an investigational CAR-T cell therapy product for B-cell malignancies, to be conducted in Turkey. The trial is registered as a single-arm study treating patients with relapsed or refractory B-cell hematological malignancies.
This registration serves as an informational notice for compliance purposes. Healthcare institutions, oncology programs, and clinical investigators should note this trial for potential competitive landscape awareness and to monitor outcomes data from this novel CAR-T manufacturing approach. No immediate compliance actions are required.
Source document (simplified)
Show glossary
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.